Schedule 13D ownership disclosure
Adamis Pharmaceuticals Corp
Security class unavailable · CUSIP: 00547W208
Event date: 2016-08-15
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 1,635,312
- Percent of class
- 7.8000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001144204-16-121751
- Form type
- SC 13D
- Filer
- DMK PHARMACEUTICALS Corp
- CIK
- CIK 887247
- Filed
- Aug 29, 2016
- Reporting period
- Aug 15, 2016
- Description
- Schedule 13D beneficial ownership